Bionxt developing sublingual semaglutide ODF system

Executive Summary

• Bionxt Solutions is advancing semaglutide as the lead candidate for its oral thin-film (ODF) platform, initiating early-stage formulation work to validate a sublingual delivery approach for GLP-1 receptor agonists.
• The company is expanding its development strategy beyond semaglutide to evaluate additional GLP-1 compounds, including tirzepatide and liraglutide, while focusing on optimizing carrier systems and film compositions for peptide delivery.
• Bionxt positions itself as a drug delivery innovator targeting the rapidly expanding GLP-1 market, with plans to generate proprietary intellectual property and pursue licensing or partnership opportunities rather than discovering new active pharmaceutical ingredients.

Key Details

• Lead Candidate & Development Stage: Semaglutide selected for early-stage development, with initial formulation work underway including preliminary feasibility and exploratory proof-of-concept evaluations.
• Platform Objective: Aims to enable sublingual delivery of complex peptide drugs, specifically GLP-1 receptor agonists, using a next-generation ODF formulation approach.
• Target Compounds: Expansion strategy includes evaluating tirzepatide and liraglutide due to shared structural and pharmacological characteristics compatible with the formulation strategy.
• Technical Focus: Development efforts are centered on identifying and optimizing carrier systems and film compositions capable of delivering large, sequence-based peptide molecules.
• Intellectual Property: Program expected to generate new IP covering formulation, carrier systems, and peptide delivery mechanisms, supporting a broader IP strategy for multicompound applications.
• Market Opportunity: Global GLP-1 receptor agonist market valued at $62.83 billion (U.S.) in 2025, projected to reach $254.19 billion by 2034 (16.8% CAGR).
• Competitive Benchmark: Novo Nordisk reported 2024 sales of ~$17.4 billion for Ozempic, ~$3.4 billion for Rybelsus, and ~$9.4 billion for total obesity care (Wegovy/Saxenda).
• Commercial Strategy: Focuses on drug delivery innovation, life cycle management for established drugs, and potential licensing/partnerships, rather than active pharmaceutical ingredient discovery.
• Trading Information: Listed on Canadian Securities Exchange (BNXT), OTC Markets (BNXTF), and trades in Germany (WKN: A3D1K3).